Diadema Partners LP Puma Biotechnology, Inc. Transaction History
Diadema Partners LP
- $391 Billion
- Q3 2025
A detailed history of Diadema Partners LP transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Diadema Partners LP holds 135,900 shares of PBYI stock, worth $672,705. This represents 0.18% of its overall portfolio holdings.
Number of Shares
135,900Holding current value
$672,705% of portfolio
0.18%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding PBYI
# of Institutions
135Shares Held
35.2MCall Options Held
264KPut Options Held
0-
Acorn Capital Advisors, LLC New York, NY4.13MShares$20.4 Million11.14% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.69MShares$18.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY3.57MShares$17.7 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.15MShares$10.6 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA2.05MShares$10.2 Million0.02% of portfolio
About PUMA BIOTECHNOLOGY, INC.
- Ticker PBYI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,556,000
- Market Cap $226M
- Description
- Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...